Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)

China · Delayed Price · Currency is CNY

2.900

0.00 (0.00%)

Oct 23, 2026, 3:04 PM CST

Market Cap	5.98B -17.6%
Revenue (ttm)	1.05B -12.4%
Net Income	-372.98M
EPS	-0.18
Shares Out	2.06B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,709,313
Open	3.140
Previous Close	2.900
Day's Range	2.720 - 3.140
52-Week Range	2.740 - 5.110
Beta	0.49
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About SHE:300267

Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets. In addition, the company off... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2003

Employees 1,271

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300267

Full Company Profile

Financial Performance

In 2025, SHE:300267's revenue was 1.17 billion, an increase of 2.29% compared to the previous year's 1.14 billion. Losses were -379.82 million, 1.73% more than in 2024.

Financial Statements